Jump to Main Content

FDA Alerts

FDA Approves Enasidenib for Adults with Relapsed or Refractory AML with an IDH2 Mutation

The U.S. Food and Drug Administration granted regular approval to enasidenib (IDHIFA, Celgene Corp.) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.